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ABSTRACT: The structure of a material, in particular the extremes of crystalline and amorphous forms, significantly impacts ma-
terial performance in numerous sectors such as semiconductors, energy storage and, in the subject of this paper, pharmaceutical 
products. To characterize the spatial distribution for crystalline-amorphous forms at the uppermost molecular surface layer, we per-
formed time-of-flight secondary-ion mass spectroscopy (ToF-SIMS) measurements for quench-cooled amorphous and recrystal-
lized samples of the drugs indomethacin, felodipine and acetaminophen. Polarized light microscopy was used to localize 
crystallinity induced in the samples under controlled conditions. Principal component analysis was used to identify the subtle 
changes in the ToF-SIMS spectra indicative of the amorphous and crystalline forms for each drug. The indicators of amorphous and 
crystalline surfaces were common in type across the three drugs, and could be explained in general terms of crystal packing and 
intermolecular bonding, leading to intramolecular chain scission in the formation of secondary ions. Less intramolecular scission 
occurred in the amorphous form, resulting in a greater intensity of molecular and dimer secondary ions. To test the generality of 
amorphous-crystalline differentiation using ToF-SIMS, a different recrystallization method was investigated where acetaminophen 
single crystals were recrystallized from supersaturated solutions. The findings indicated that the ability to assign the crystal-
line/amorphous state of the sample using ToF-SIMS was insensitive to the recrystallization method. This demonstrates ToF-SIMS 
capabilities of detecting and mapping ordered crystalline and disordered amorphous molecular materials forms at micron spatial 
resolution in the uppermost surface of a material. 
The order and disorder of molecules in a solid material af-
fect its surface activity, electrical, optical and many more 
properties with an impact in numerous industrial sectors, such 
as semiconductors
1
, structural materials
2
, energy storage
3
 and 
pharmaceuticals
4
. In pharmaceutical manufacturing, there is an 
increasing drive to ensure the pharmaceutical products quality 
from the design stage
5
 by predicting and controlling the physi-
cal, chemical and pharmacological interactions that affect the 
bioavailability of the pharmaceutical end product. One of the 
most common, undesirable, difficult to control and to predict 
phenomena during the production of solid dosage forms (e.g. 
granules, capsules, tablets and inhalable dry powders) is the 
crystalline-amorphous transformation. 
Crystalline and amorphous materials impact the pharmaceu-
tical end product
4
 by altering the chemical and physical stabil-
ity, for example the kinetics of drug dissolution and the kinet-
ics of recrystallization. Furthermore, crystalline and amor-
phous materials distributed at the surface of pharmaceutical 
powder particles affect how particles interact with each other
6
, 
which in turn alters the powder behavior during aggregation or 
dispersion
6-8
. While the quantification of amorphous-
crystalline materials has been investigated by numerous non-
spatially resolved techniques
9-11
, spatial distribution is consid-
erably more challenging to assess at the surface of materials.  
Presently, only confocal Raman spectroscopy
12,13
 and atom-
ic force microscopy (AFM)
6
 have been used to successfully 
localize amorphous areas. Although an excellent technique for 
polymorphic form determination, confocal Raman has a sam-
pling depth resolution of 1-2 μm
14
 that does not address the 
first nanometers where the particle-particle interaction occurs. 
AFM has surface specificity, however it also has drawbacks 
associated with time consuming data acquisition, a relatively 
small area of analysis (usually much less than 100 μm × 100 
μm), a requirement for very flat samples and strong artefacts 
that can lead to erroneous identification of a material as amor-
phous material
6
. 
An alternative analytical technique is time-of-flight second-
ary-ion mass spectrometry (ToF-SIMS), which is highly sur-
face specific and exhibits an information depth of 2 atomic 
layers
15
 to 10 atomic layers
16
 (uppermost 0.5-3 nm, depending 
on the material), a lateral resolution greater than 200 nm and 
considerably shorter data acquisition time than Raman and 
AFM mapping.  
For non-molecular materials such as metals, the removal of 
surface atoms due to energetic particle bombardment (sputter-
ing) is known to be strongly influenced by the crystalline ori-
entation of the material.
17
 However, materials comprised of 
molecules present a more complex situation and structural 
information from ToF-SIMS has only been published in three 
cases known to the authors. 
Li et al. noted
18
 the crystallization of the amorphous co-
polymer of bisphenol A and 1,8-dibromooctane resulted in a 
molecular structure consisting of stacked layers of polymer 
  
2 
with an easily identifiable terminal bromine group displayed 
on the surface of the polymer film. Lau et al.
19
 noted the crys-
tallization of the surfaces of poly(bisphenol A-etheroctanes), 
poly(bisphenol A-etherdecanes) and poly(bisphenol A-
etherdodecanes), where the flexible-segment length increased 
from 8 to 10 CH2 units resulted in an increase in the intensity 
of the flexible-segment folds over the rigid-segment folds as-
sessed with ToF-SIMS. 
In the only other example, Muster and Prestidge
20
 achieved 
structural determination of molecular materials with ToF-
SIMS on single crystals of N,N-octyl-D-gluconamide and 
sulfathiazole where several fragment ions and their intensities 
were found to be correlated with specific crystal faces. For 
example, the sulfathiazole molecular ion was associated with 
the [102] crystal face where the molecular layers were less 
associated among themselves, as assessed using the molecular 
ion intensity normalized to the total ion counts and the crystal-
lographic information.
20
 
In this work we consider three drugs where controlled re-
crystallization of amorphous surfaces has been employed to 
obtain distinct crystalline regions in an amorphous continuum. 
The drugs (indomethacin, felodipine and acetaminophen) were 
chosen for their amorphous form stability and molecular 
weight range being typical for pharmaceutical drugs, between 
m/z = 100 and m/z = 400. Using multivariate analysis we iden-
tify secondary ions indicative of each structurally distinct re-
gion and we develop a general rationale for the observation of 
structural differences in the ToF-SIMS data from molecular 
materials which we propose will have application in other 
material science sectors. 
EXPERIMENTAL SECTION 
Sample preparation. Acetaminophen (form I polymorph) 
of purity ≥ 99.0 % and indomethacin (γ-form polymorph) of 
purity ≥ 99.0 % were purchased from Sigma-Aldrich (Dorset, 
UK). Felodipine (3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, form I poly-
morph) was provided by AstraZeneca (Södertälje, Sweden). 
Analytical grade solvents were obtained from Fisher Scientific 
(Loughborough, UK). The water was purified by reverse os-
mosis using Merck Millipore Milli-Q System (Molsheim, 
France).  
Indomethacin and felodipine. The as-received drug was 
placed between two glass slides and melted at 200 °C on a 
Linkam Scientific LTS350 thermal stage (Tadworth, UK) with 
a heating rate of 30 °C / min. The melted sample between the 
glass slides was then immersed into liquid nitrogen. The glass 
slides were then separated, leaving a film of quench cooled 
drug on the slides. The film was scratched with a metal needle 
to initiate crystallization and then left for 1 h in a Thermo 
Fisher Scientific Hereaus VT 6025 vacuum oven (Waltham, 
MA) at 80 °C and 1 × 10
-2
 mbar. The recrystallized areas were 
detectable by polarized light microscopy (PLM) after 1 h. For 
indomethacin, the recrystallized areas were confirmed as α-
form (Figures 1-5 of the Supporting Information). The recrys-
tallized felodipine was confirmed as form I (Figures 6 and 7 of 
the Supporting Information). 
Acetaminophen. The as-received drug was melted onto a 
glass slide at 160 °C using the LTS350 thermal stage. The 
melted sample was mounted on the SIMS cryo stage at room 
temperature, then liquid nitrogen was poured to quench cool it. 
The sample was placed in the instrument air lock which had 
been pre-cooled to -40 °C. Exposure to room conditions was 
kept to less than 10 seconds to maintain surface amorphicity 
for acetaminophen. Following the ToF-SIMS analysis of the 
amorphous surface, visually monitored recrystallization of the 
amorphous sample was performed by exposure to ambient 
conditions for 30 min. The recrystallized acetaminophen was 
confirmed as type I (Figure 8A,B of the Supporting Infor-
mation). Aqueous supersaturated solutions of acetaminophen 
were prepared by heating the solution to 70 °C for 30 min, 
using a supersaturation level above 50%.
21
 The resulting crys-
tals were extracted through a 1 cm deep layer of toluene and 
washed with additional toluene to stop crystal growth.
22
 The 
crystals were placed in the vacuum oven at 80 °C and 1 × 10
-2
 
mbar for 12 h to remove any toluene.  
ToF-SIMS. ION-TOF IV instrument (Münster, Germany) 
equipped with a single-stage reflectron analyzer and a bismuth 
liquid metal ion gun was used. The analysis was conducted in 
high current-bunched mode for optimal mass resolution with 
Bi3
+ 
primary ions. The primary ion gun energy was 25 kV and 
the pulsed target current was approximately 0.3 pA.  
For indomethacin and felodipine ToF-SIMS analysis was 
performed immediately on the same crystallized areas identi-
fied with PLM for areas of 500 μm × 500 μm, at a resolution 
of 1024 × 1024 pixels, for 12 scans. These conditions ensured 
a primary ion dose intensity of 9.42 × 10
11
 (primary ions/ 
cm
2
). For acetaminophen, ToF-SIMS analysis was performed 
for areas of 100 μm × 100 μm, at a resolution of 256 × 256 
pixels, for 8 scans (with one shot per pixel) and primary ion 
dose intensity of 9.81 × 10
11
 (primary ions/ cm
2
), comparable 
with the dose intensity for indomethacin and for felodipine. 
Positive and negative polarity data were acquired for this 
study. Positive polarity results are presented for indomethacin, 
whereas negative polarity results are presented for acetamino-
phen and felodipine. The discussion of the remaining results is 
provided in the Supporting Information the Multivariate data 
analysis discussion section. The mass range of the peaks was 
m/z = 0-800. The calibration of the spectra followed the pro-
cedure recommended by Green et al.
23
. For indomethacin, the 
spectra were calibrated using the CH3
+
, C2H3
+
, C3H7
+
and 
C4H9
+
, C5H11
+
 and C19H16NO4Cl
+
 ([M]
+
) fragment ions. For 
felodipine, negative polarity ion spectra were calibrated using 
the CH
-
, C2H
-
, C3H
-
, C4H
-
, C5H
-
, C6H5Cl
-
 and the 
C18H17NO4Cl2K
-
 ([M]
-
) fragment ions. For acetaminophen, 
negative polarity ion spectra were calibrated using the CH
-
, 
C2H
-
, C3H
-
, C4H
-
, C5H
-
, and C8H9NO2
-
 ([M]
-
) fragment ions. 
The obtained calibration deviations were below 50 ppm. 
All peaks for a signal-to-noise ratio of 100 as detected by 
the ION-TOF SurfaceLab 6.4 software (Münster, Germany) 
and manually-added smaller peaks were integrated. The inte-
gration limits were manually checked for each detected peak. 
The identity of the secondary ions was assigned based on the 
lowest standard deviation, as computed by SurfaceLab 6.4 
software, taking into consideration the reference spectra for 
indomethacin, felodipine and acetaminophen present in 
mzCloud
24
 mass spectral database. ToF-SIMS spectra were 
then exported using a detector dead time correction and used 
in the multivariate analysis. The initial spectra are presented in 
Figures 11-14 of the Supporting Information.  
  
3 
Multivariate data analysis. PLS Toolbox v. 2.0 (Eigenvec-
tor Research, Manson, WA) for MATLAB (the MathWorks, 
Inc., Natick, MA) was used for principal component analysis 
(PCA). Prior to PCA, SIMS data were normalized to total 
counts to reduce changes in signal due to topography and in-
strumental conditions.
25
 Then Poisson scaling was used to 
account for the absolute measurement uncertainty of the ToF-
SIMS detector.26. Lastly, the data was mean centered so that 
the variance in the dataset is due to sample variances instead 
of differences in sample means.
27
 The significance of the 
amorphous-recrystallized group separations in the PCA scores 
plots was calculated using the method described by Worley et 
al
28
.  
Polarized light microscopy. The polarized filters Prior Sci-
entific PriorLux POL (Cambridge, UK) were together with the 
attached QImaging camera (Surrey, Canada). 
RESULTS AND DISCUSSION 
Crystalline materials expose different chemical groups at 
each crystal faces
29
 as a result of the molecular order in the 
crystalline lattice. Amorphous materials do not possess a crys-
talline lattice nor long-range molecular order and hence ran-
dom groups are present at their surface. The secondary ions 
detected in ToF-SIMS emerge from the molecules making up 
the surface and therefore will be strongly influenced by the 
molecular arrangement
16
. We therefore investigate whether the 
different surface structures between polycrystalline and amor-
phous areas of the same material lead to differences in their 
secondary-ion mass spectra.  
Firstly we present the results for the amorphous, quench-
cooled surfaces and the recrystallized surfaces chemically 
mapped using ToF-SIMS. Secondly, in order to test the gener-
ality of our observations, we compare the findings with the 
ToF-SIMS information from samples prepared through a dif-
ferent crystallization method typically found in the pharma-
ceutical industry, that is the recrystallization from supersatu-
rated solutions of acetaminophen crystals. 
Indomethacin. Polarized light microscopy (PLM) of the in-
domethacin samples after recrystallization revealed localized 
crystalline features on a continuum substrate of amorphous 
film shown in Figure 1A. The freshly crystallized features 
could not be detected with confocal Raman spectroscopy, the 
data for which is shown in Figures 1-5 of the Supporting In-
formation. It is proposed that the crystallized features are sur-
face localized due to the scratch initiation used and are less 
than 1 μm deep in depth which leads to a convoluted crystal-
line signal, outweighed by the underlying amorphous signal, 
due to the information depth specific to Raman spectroscopy.
14
 
ToF-SIMS images were subdivided, cropping the amor-
phous and the crystalline regions of interest, as identified by 
the C6H16N
+
 fragment ion (m/z = 102.13) that was present in 
the amorphous areas and absent in the crystalline areas. The 
crystalline and amorphous areas were subdivided into smaller 
regions of interest that were treated as individual samples to 
ensure improved statistics for PCA. The scores plot in Figure 
1D indicates the discrimination of amorphous areas from crys-
talline areas.  
Amorphous areas present positive scores on principal com-
ponent one (PC 1) capturing 55.28 % of total variation in the 
dataset, whereas crystalline areas present negative scores. This 
segregation is significant, as shown in Figure 1E. The loadings 
plot shown in Figure 1F indicates the chemical fragments cor-
related with the amorphous surfaces and with the crystalline 
surfaces. Fragment ions with positive values indicate amor-
phous surfaces and originate from the indole part of the mole-
cule whereas fragments with negative values indicate crystal-
line surfaces present and originate from the chlorobenzoyl part 
of the molecule (Charts1,2 of the Supporting Information). For 
example, the secondary ions C6H16N
+
 (m/z = 102.12), NH4
+
 
(m/z = 18.03), C4H10N
+
 (m/z = 86.10), C6H11N
+
 (m/z = 97.07) 
and the molecular ion C19H16NO4Cl
+
 ([M]
+
, m/z = 357.07) are 
associated with the amorphous form (Figure 1F). These sec-
ondary ions originate from the indole ring of the indomethacin 
molecule.  
Crystal structures for indomethacin show the indole ring is 
overlapping with the acetic acid group of another molecule 
where the tri-molecular arrangement specific to α-
indomethacin
30
 leads to a less exposed indole ring. 
In the amorphous state there is no crystalline lattice and the 
molecule is not as strongly bound by its neighbors as it is in 
the crystalline form. We propose that this leads to a more fa-
vored production of the molecular ion [M]
+
 from the amor-
phous state than the fragmented secondary ions originating 
from the indole ring of the molecule. Crystalline areas have 
negative scores values and present negative loadings values 
(Figure 1F) with secondary ions originating from the 
chlorobenzoyl ring: C7H5OCl
+
 (m/z = 141.00), C6H4Cl
+
 (m/z = 
110.99) andC6H
+
 (m/z = 73.00). Smaller fragments, such as 
C4H3
+
 (m/z = 51.00), C5H3
+
 (m/z = 63.00) are also correlated 
with the crystalline surfaces and are originating most likely 
from the breakage of the benzoyl ring.  
Therefore, SIMS imaging together with polarized light mi-
croscopy and multivariate analysis has demonstrated the clear 
differentiation of the crystal molecular arrangement between 
the recrystallized features and quench-cooled amorphous films 
for indomethacin. 
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Smaller fragments,such as C4H3
+
 (m/z = 51.00), C5H3
+
 (m/z 
= 63.00) are also correlated with the crystalline surfaces and 
are originating most likely from the breakage of the benzoyl 
ring.  
Therefore, SIMS imaging together with polarized light mi-
croscopy and multivariate analysis has demonstrated the clear 
differentiation of the crystal molecular arrangement between 
the recrystallized features and quench-cooled amorphous films 
for indomethacin 
Figure 1. Indomethacin crystalline nuclei on amorphous quench cooled films observed by two microscopy techniques: (A) polarized mi-
croscopy and ToF-SIMS imaging of (B) C6H16N
+ secondary ion (m/z = 102.13) and (C) C6H4Cl
+ secondary ion (m/z = 110.99) normalized 
to the total ion image to remove topographical effects. (D) Scores plot on PC 1 for indomethacin subdivided areas of the recrystallized 
surface and the amorphous surface, using positive ion spectra. (E) Dendrogram generated from scores in (D) using Mahalanobis distances, 
with p values for the null hypothesis. (F) Loadings vector plotted as loadings coefficient versus peak m/z for the data set (model with three 
latent variables). Eigenvalue plot and principal component number selection are shown in Figure 15A of the Supporting Information. 
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Figure 2. Felodipine crystalline nuclei on amorphous quench-cooled films observed by two microscopy techniques: (A) polarized micros-
copy; and ToF-SIMS imaging of (B) C5Cl
- secondary ion (m/z = 94.97) and (C) C3NO
- secondary ion (m/z = 66.00) normalized to the total 
ion image to remove topographical effects (D). Scores plot on PC 1 for felodipine subdivided areas of the recrystallized surface and the 
amorphous surface, using negative ion spectra. (E) Dendrogram generated from scores in (D) using Mahalanobis distances, with p values 
for the null hypothesis. (F) Loadings vector plotted as loadings coefficient versus peak m/z for the data set (model with three latent varia-
bles). Eigenvalue plot and principal component number selection are shown in Figure 19A of the Supporting Information. 
Felodipine. Crystallized areas were detected for felodipine 
with PLM (Figure 2A) and ToF-SIMS imaging (Figure 2B,C). 
The amorphous area in ToF-SIMS can be identified by the 
presence of C5Cl
- 
(m/z = 94.97), shown in Figure 2B. The 
crystalline area can be identified by the presence of C3NO
+
 
(m/z = 66.00), shown in Figure 2C. The amorphous area used 
for the PCA analyses is not that shown in Figure 4. There was 
too little amorphous area in Figure 4 to ensure reliable statis-
tics for the multivariate analyses and the crystallized areas 
were visibly higher than the amorphous substrate. Therefore, a 
separate ToF-SIMS image of a larger amorphous region was 
acquired and subdivided in smaller areas for the PCA and 
PLS-DA analyses. In the centre of the crystallized area a de-
pression was present (Figure 2A), which led to signal loss in 
that area for the secondary ions characteristic for crystalline 
surfaces (Figure 2C). Hence, the data for the crystalline area 
was subdivided into smaller areas that excluded the depres-
sion. 
Crystalline and amorphous surfaces could be discriminated 
on PC 1, which captures 67.81% of the total variance in the 
dataset. The multivariate analysis shows the significant separa-
tion of the amorphous-recrystallized groups (Figures 2D,E). 
(D) 
(E) 
(F) 
(A) (B) (C) 
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The ions correlated with the amorphous areas present positive 
values in the loadings plot, whereas the ions correlated with 
the crystalline areas present negative values, as shown in Fig-
ure 2F. 
The crystalline form was indicated by secondary ions result-
ing from the fragmentation of the dichlorophenyl ring or from 
the fragmentation of the intermolecular CN-H···O hydrogen 
bond between the pyridyl N atom to the carboxyl O atoms of 
the methyl or ethyl ester
31
, such as C6H3Cl2
-
 (m/z = 145.00), 
C8H
-
 (m/z = 97.00),C6H
-
 (m/z = 73.00), C3N
-
 (m/z = 50.00), 
C3NO
-
 (m/z = 65.99) and CN
-
 (m/z = 26.00). The amorphous 
form was indicated by the presence of the quasi-molecular ion 
[M-H2]
-
 (C18H17Cl2NO4
-
, m/z = 381.76), Cl
-
 (m/z = 34.97), 
C12H14NO4
-
 (m/z = 236.08 ), C8H7NO2
-
 (m/z = 149.00) , 
C9H11NO2
- 
(m/z = 165.00) and C10H13NO2
-
 (m/z = 179.00). 
The secondary ions correlated with the amorphous form ei-
ther contain an intact dihydropyridine ring or originate from 
the breakage of the dihydropyridine ring. Crystal structures for 
felodipine show the parallel dihydropyridne rings are inter-
twined in a mesh with 90°-oriented dichlorophenyl rings act-
ing as the links between the parallel stacks of dihydropyridine. 
This molecular arrangement leads to a less exposed 
dihydropyridine ring.
32
 While the dihydropyridne rings are 
less exposed by their arrangement in the intertwined mesh 
with the intermolecular dichlorophenyl rings, the 
dichlorophenyl fraction is “sticking out” at the surface of 
felodipine crystals.
32
 Furthermore, all four polymorphs
31
 of 
crystalline felodipine exhibit intermolecular CN-H···O hydro-
gen bonds from the pyridyl N atom and the carboxyl O atom 
of the methyl/ethyl ester.  
In the amorphous state there is no crystalline lattice and the 
molecule is not as strongly bound by its neighbors as it is in 
the crystalline form. We propose that this molecular arrange-
ment leads to a more favored production of the molecular ion 
[M-H2]
-
 (C18H17Cl2NO4
-
 ,m/z = 381.76) from the amorphous 
state than the fragmented secondary ions originating from the 
dichlorophenyl of the molecule. Therefore, SIMS imaging 
together with polarized light microscopy and multivariate 
analysis has demonstrated the clear differentiation of the crys-
tal molecular arrangement between the recrystallized features 
and quench-cooled amorphous films for felodipine. 
Acetaminophen. In the pharmaceutical industry there are 
numerous cases of drugs with unstable amorphous forms 
where varying degrees of amorphous material can lead to 
problems during pharmaceutical manufacturing and during the 
commercialization of the pharmaceutical product. Although 
not used in its amorphous form, acetaminophen represents one 
of these cases where the amorphous form is very unstable and 
exhibits a fast crystallization rate on the order of minutes
13
. 
Therefore, crystallized areas on amorphous films could not be 
imaged by both PLM and SIMS because of the rapid recrystal-
lization of the amorphous form. The acetaminophen samples 
were analyzed before and after recrystallization and were con-
firmed as form I. The identity of the amorphous and recrystal-
lized samples was ascertained by Raman spectroscopy, shown 
in Figure 8A,B of the Supporting Information. 
 
 
 
Figure 3. PCA of acetaminophen subdivided areas of the recrys-
tallized surface and the amorphous surface: (A) Scores plot for PC 
1 using negative ion spectra. (B) Loadings vector plotted as load-
ings coefficient versus peak m/z for the data set (model with three 
principal components). Eigenvalue plot and principal component 
number selection are shown in Figure 23A of the Supporting In-
formation). 
Amorphous and recrystallized surfaces were discriminated 
on PC 1 (78. 05 % of the total variation in the dataset), with 
positive scores values for amorphous surfaces and negative 
scores values for crystalline surfaces (Figure 3A). The p value 
(9.47e-007) calculated using Mahalanobis distances indicated 
a clear segregation for the 2 clusters. The loadings coefficients 
in Figure 3B identify the secondary ions correlated with amor-
phous surfaces (positive values) and crystalline surfaces 
(negative values). The secondary ions correlated with amor-
phous acetaminophen were the quasi-molecular ion C8H8NO2
-
 
([M-H]-, m/z = 150.06), the quasi-dimer ion [2M-H3]
-
 (m/z = 
299.09), O
-
 (m/z = 15.99), OH
-
 (m/z = 17.00) and C2
-
 (m/z = 
24.00).  
These findings can be explained, as with indomethacin and 
felodipine, based on the acetaminophen crystal structure. 
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Figure 4. Scores plot on PC 1 for PCA of acetaminophen amorphous, recrystallized and single crystal surfaces. Negative ion spectra were 
used. The eigenvalue plot and the loadings plot are shown in Figure 27A,C of the Supporting Information. The p values calculated using 
Mahalanobis distances indicated a clear segregation (p value = 6.3e-006) for the amorphous cluster and the cluster formed of recrystal-
lized, and the three crystal faces. 
The acetaminophen crystal structure is determined by in-
termolecular hydrogen bonds, with each molecule being linked 
to another four acetaminophen molecules
33
. We propose that 
the absence of intermolecular bonds between the neighboring 
molecules specific to amorphous materials leads to a more 
favored production of the molecular ion C8H8NO2
-
. 
The correlation of the OH
-
 (m/z = 17.00) and O
-
 (m/z = 
15.99) fragment ions with the amorphous form can be ex-
plained by the same absence of the hydrogen intermolecular 
bonds, which results in free OH groups leading to a higher 
yield of O
-
 and OH
-
 in comparison with the crystalline form 
where the hydroxyl groups are engaged together with the am-
ide groups in hydrogen bonds. Crystalline surfaces were indi-
cated by secondary ions such as C7H4NO2
-
 (m/z = 134.02), 
CNO
-
 (m/z = 42.00).  
We observed that the crystalline form is correlated with the 
secondary fragment ions originating from the breakage of in-
termolecular bonds, producing fragments such as C3NO
-
 (m/z 
= 66.00) and C6H5NO
-
 (m/z = 107.03) ions.  
To test the generality of amorphous-crystalline differentia-
tion using ToF-SIMS, acetaminophen crystals were recrystal-
lized from super-saturated solutions. The newly produced 
crystals were confirmed as acetaminophen polymorph form I 
(Figure 8A, B in the Supporting Information). The XRD anal-
ysis confirmed the presence of a single crystal with three dis-
tinct faces (Figure 9F of the Supporting Information). The 
crystal faces were identified based on their morphology using 
Cambridge Structural Database
34
 and Mercury 2.2
35
 (Figure 
9A-E of the Supporting Information). The surface of the crys-
tal faces was imaged using atomic force microscopy. The data 
are shown in Figure 10A-F of the Supporting Information. 
PCA shows that crystal faces are similar to recrystallized 
surfaces and both of them are different from amorphous sur-
faces (Figure 4). 
Whilst it is not the purpose of this work, it is interesting to 
note that there are not differences between different crystal 
faces and recrystallized surfaces, as opposed to the findings of 
one previous work
20
. Muster and Prestidge 
20
 have shown that 
recrystallization from saturated solutions in controlled condi-
tions can produce crystals where crystal faces exhibit different 
chemistries that can lead to differences in their SIMS spectra. 
However, both their analyzed crystals N,N-octyl-D-
gluconamide and sulfathiazole were cleaved in order to expose 
contamination-free surfaces. As opposed to their method, in 
our work the acetaminophen crystals were analyzed without 
prior truncation, in order to simulate the typical crystal grow-
ing conditions seen in the pharmaceutical industry. Thus, the 
non-cleaved acetaminophen crystal faces were more likely to 
exhibit lattice defects, contaminants and various crystal habits 
that could obscure the differences among different crystal fac-
es and recrystallized surfaces in a PCA analysis. The same 
fragment ions were correlated with amorphous and with crys-
talline surfaces (Figure 27C of the Supporting Information) as 
the ones identified by analyzing only the recrystallized and 
quench-cooled amorphous surfaces (Figure 3B). 
Therefore, SIMS imaging together with polarized light mi-
croscopy and multivariate analysis has again demonstrated the 
clear differentiation of the crystal molecular arrangement be-
tween the amorphous surfaces and crystalline surfaces manu-
factured in two different ways for acetaminophen. The pres-
ence of lattice defects, bound to occur in any crystallization 
phenomenon, do not seem to affect the amorphous-crystalline 
discrimination seen with ToF-SIMS in Figures 3 and 4, how-
ever further investigations are necessary to confirm this hy-
pothesis. These findings strengthen the argument for the usage 
of ToF-SIMS imaging to detect and to map polycrystalline and 
amorphous surfaces for drug films that could be further ex-
tended for drug particles characterization. 
CONCLUSION 
We demonstrated that ToF-SIMS imaging using Bi3
+
 prima-
ry ions can be used as a reliable method to identify amorphous 
and crystalline surfaces for drugs, exemplified using indo-
methacin, felodipine and acetaminophen. The crystalline sur-
faces are indicated by secondary ion fragments resulting from 
intramolecular and intermolecular bond scission, whereas the 
amorphous surfaces are indicated by molecular ions and di-
mers.  
Different recrystallization methods do not affect this general 
difference between amorphous and crystalline surfaces. These 
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findings enable enhanced surface characterization for ordered 
and disordered molecular systems, with implications for poor-
ly understood interfacial processes, such as powder behavior, 
catalysis surface performance and semiconductor manufactur-
ing quality control. For pharmaceutical materials, the ability to 
analyze the spatial surface distribution of crystalline and 
amorphous regions will add to our knowledge of the interac-
tions between solid surfaces 
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available free of charge via the Internet at http://pubs.acs.org.  
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